No Priors AI Paradromius Wins FDA Approval for High-Bandwidth BCI Trial
Nov 20, 2025
A groundbreaking FDA-approved trial for a high-resolution brain-computer interface is unveiled, with the potential to restore fluent speech for those with severe motor disabilities. The innovative Conexus implant boasts over 400 electrodes, allowing rapid neuron activity recording. Initial trials focus on safety and accuracy, while ambitious animal-test results suggest fast communication rates. The discussion also covers ethical concerns and the competitive landscape of neurotechnology. This trial could mark a significant milestone in transforming lives.
AI Snips
Chapters
Transcript
Episode notes
High-Resolution, High-Bandwidth BCI
- Paradromics' Conexus records from individual neurons using 400+ ultra-thin microwire electrodes in motor cortex.
- Animal tests showed transfer rates ~200 bits/sec, suggesting much higher communication bandwidth than many BCIs.
Aiming To Restore Fluent Speech
- High data flow could let users communicate far faster than current assistive devices.
- Paradromics aims to translate neural intent into text and synthetic speech by reading attempted speech signals.
Prioritize Safety And Stability First
- Monitor safety and long-term stability closely in early trials with very few participants.
- Prove safe implantation, device longevity, and accurate decoding before expanding the study.